Wedbush reaffirmed their outperform rating on shares of Stemline Therapeutics (NASDAQ:STML) in a research report report published on Monday, November 12th. They currently have a $22.00 target price on the biopharmaceutical company’s stock. Wedbush also issued estimates for Stemline Therapeutics’ Q4 2018 earnings at ($0.67) EPS, FY2018 earnings at ($2.75) EPS, Q1 2019 earnings at ($0.52) EPS, Q2 2019 earnings at ($0.46) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.43) EPS, FY2019 earnings at ($1.86) EPS, FY2020 earnings at ($1.35) EPS, FY2021 earnings at ($0.31) EPS and FY2022 earnings at $1.12 EPS.
Several other brokerages have also recently issued reports on STML. ValuEngine raised shares of Stemline Therapeutics from a hold rating to a buy rating in a research note on Tuesday, August 14th. BidaskClub upgraded shares of Stemline Therapeutics from a sell rating to a hold rating in a report on Tuesday, July 24th. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the company a buy rating in a research note on Monday, November 12th. Finally, Zacks Investment Research upgraded shares of Stemline Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $26.32.
STML stock traded down $0.30 during midday trading on Monday, hitting $10.17. The stock had a trading volume of 433,600 shares, compared to its average volume of 259,280. The stock has a market capitalization of $332.95 million, a P/E ratio of -3.46 and a beta of 0.64. Stemline Therapeutics has a 12-month low of $9.98 and a 12-month high of $20.55.
Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). On average, equities analysts anticipate that Stemline Therapeutics will post -2.8 earnings per share for the current year.
In related news, COO Kenneth Hoberman sold 26,296 shares of Stemline Therapeutics stock in a transaction dated Monday, November 26th. The shares were sold at an average price of $11.85, for a total transaction of $311,607.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 14.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. BlueMountain Capital Management LLC acquired a new stake in Stemline Therapeutics in the 2nd quarter valued at about $137,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $166,000. MetLife Investment Advisors LLC grew its position in shares of Stemline Therapeutics by 54.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 6,527 shares during the period. Bank of America Corp DE grew its position in shares of Stemline Therapeutics by 97.8% during the 2nd quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 10,159 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $344,000. Hedge funds and other institutional investors own 64.20% of the company’s stock.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Featured Article: What is a bull market?